Item 2.02. Results of Operations and Financial Condition

On March 27, 2023, Acer Therapeutics Inc. filed its Annual Report on Form 10-K for the year ended December 31, 2022 and announced the results of operations in a press release. A copy of the press release announcing the results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure

The Company has updated its Corporate Presentation that will be available on the Investor Relations page of the Company's website at https://acertx.com/investor-relations and will be used at investor and other meetings. A copy of the updated Corporate Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company does not undertake to update this presentation.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit
  No.                                      Description


99.1         Press release issued by Acer Therapeutics Inc. on March 27, 2023.

99.2         Acer Therapeutics Inc. Corporate Presentation, March 27, 2023.

104        Cover page interactive data file (embedded within the inline XBRL document).







                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses